

1 **Bacteriophages targeting protective commensals impair resistance**
2 **against *Salmonella* Typhimurium infection in gnotobiotic mice**

3

4 Alexandra von Strempel¹, Anna S. Weiss¹, Johannes Wittmann², Marta Salvado Silva¹, Diana
5 Ring¹, Esther Wortmann³, Thomas Clavel³, Laurent Debarbieux⁴, Karin Kleigrewe⁵, Bärbel
6 Stecher^{1,6*}

7

8 ¹ Max von Pettenkofer Institute of Hygiene and Medical Microbiology, Faculty of Medicine,
9 LMU Munich, Munich, Germany

10 ² Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH,
11 Braunschweig, Germany

12 ³ Functional Microbiome Research Group, Institute of Medical Microbiology, University
13 Hospital of RWTH Aachen, Aachen, Germany

14 ⁴ Institut Pasteur, Université Paris Cité, CNRS UMR6047, Bacteriophage Bacterium Host,
15 Paris 75015, France

16 ⁵ Bavarian Center for Biomolecular Mass Spectrometry, TUM School of Life Sciences,
17 Technical University of Munich, Freising, Germany

18 ⁶ German Center for Infection Research (DZIF), partner site LMU Munich, Munich, Germany

19

20 *corresponding author

21 Email: stecher@mvp.lmu.de

22

23

24

25

26

27

28

29

30

31

32

33

34 **Abstract**

35 Gut microbial communities protect the host against a variety of major human gastrointestinal
36 pathogens. Bacteriophages (phages) are ubiquitous in nature and frequently ingested via food
37 and drinking water. Moreover, they are an attractive tool for microbiome engineering due to
38 the lack of known serious adverse effects on the host. However, the functional role of phages
39 within the gastrointestinal microbiome remain poorly understood. Here, we investigated the
40 effects of microbiota-directed phages on infection with the human enteric pathogen *Salmonella*
41 *enterica* serovar Typhimurium (*S. Tm*), using a gnotobiotic mouse model (OMM¹²) for
42 colonization resistance (CR). We show that phage cocktails targeting *Escherichia coli* and
43 *Enterococcus faecalis* acted in a strain-specific manner. They transiently reduced the population
44 density of their respective target before establishing coexistence for up to 9 days. Infection
45 susceptibility to *S. Tm* was markedly increased at an early time point after phage challenge.
46 Surprisingly, OMM¹² mice were more susceptible 7 days after a single phage inoculation, when
47 the targeted bacterial populations were back to pre-phage administration density. The presence
48 of phages that dynamically modulates the density of protective members of the gut microbiota
49 provides opportunities for invasion of bacterial pathogens.

50

51 **Key words**

52 Gut microbiota; Oligo-Mouse-Microbiota, OMM¹², sDMDMm2, synthetic microbial
53 community; *Salmonella* infection; drinking water; colitis; coexistence

54

55 **Introduction**

56 The human intestine is a complex and highly dynamic microbial ecosystem, which consists of
57 trillions of microorganisms, predominantly bacteria (1). In addition to other important
58 functions, the gut microbiome forms a protective barrier against human pathogens such as
59 *Salmonella*, *Clostridioides difficile* or multi-resistant Gram-negative Bacteria (MRGN), termed
60 colonization resistance (CR). Mechanisms underlying CR include substrate competition,
61 production of bacteriocins or toxic metabolites or initiation of host immune responses (2). CR
62 is higher in hosts with a complex microbiota and generally disrupted by drugs (3), dietary
63 factors (4, 5) and diseases (6), but was also shown to be highly variable among healthy human
64 individuals (7, 8). Other risk factors may exist, which are currently still unknown.

65 Besides bacteria, the human microbiome also includes viruses, amongst which bacteriophages,
66 the viruses that predate on bacteria, are highly abundant (9, 10). Previous studies reported that
67 phages can impact the bacterial community (11, 12) and influence bacterial population
68 structures, functions and the metabolome by interacting with their bacterial hosts. Metagenomic
69 studies identified largely temperate phages in the gut microbiota (13) and showed that their
70 activation can be triggered by various environmental inducers including diet (14, 15). Virulent
71 phages are also found in the mammalian gut (16) where they can coexist with their host bacteria
72 over time (17) and thereby also functionally impact bacterial communities (11). Although
73 metagenomic studies have addressed the abundance, diversity, individuality and stability of
74 phages in the gut (18), little is known about the role of virulent phages in regulating intestinal
75 microbiome functions.

76 In this work, we investigated the effect of two virulent phage cocktails targeting *Escherichia*
77 *coli* and *Enterococcus faecalis* on the microbial community and CR against human pathogenic
78 *Salmonella enterica* serovar Typhimurium (*S. Tm*). We used a gnotobiotic mouse model for
79 CR, based on the Oligo-Mouse-Microbiota (OMM¹²), a synthetic bacterial community for
80 functional microbiome research (19). The OMM¹² consists of 12 bacterial strains representing
81 the five major phyla in the mouse gut, which was recently characterized *in vitro* (20) and can
82 be extended by bacterial strains to provide additive functions. Here, we amended the OMM¹²
83 with two additional members, *E. coli* Mt1B1 and the secondary bile acid producer *Extibacter*
84 *muris* DSM 28560 to enhance CR against gastrointestinal pathogens (OMM¹⁴) (21). Recent
85 studies showed that *E. coli* Mt1B1 and *E. faecalis* KB1 are involved in mediating CR against
86 *S. Tm* in the community context. These two bacterial species are frequently challenged by
87 virulent phages present in the environment and that could reach the gut via drinking water and
88 food (22, 23). We addressed the impact of phages targeting *E. coli* and *E. faecalis* on
89 microbiome functions *in vivo* and *in vitro* and their global effect on the members of a synthetic
90 gut community. By targeting bacteria that play a role in mediating CR against *S. Tm*, we show
91 that phages impair CR and facilitate pathogen invasion.

92

93

94 Results

95

96 Phage isolation and characterization

97 To target *E. coli* Mt1B1 we selected three virulent phages, Mt1B1_P3, Mt1B1_P10 and
98 Mt1B1_P17 (short: P3, P10 and P17), which were previously characterized and shown to stably
99 coexist with their host strain in gnotobiotic mice (17). P3 and P10 are podoviruses and belong
100 to the genus *Teseptimavirus* and *Zindervirus*, respectively, whereas P17 shows characteristic
101 features of a myovirus (**Table 1**). In accordance with Lourenco et al. (17), we found that all
102 three phages individually inhibited *E. coli* Mt1B1 growth *in vitro* and showed strongest
103 inhibition when added together (**S1A Fig**). In previous studies, the host range of the individual
104 phages was tested against several different *E. coli* strains (17, 24). It was shown that phage P17
105 exhibited a rather broad host range whereas the host range of P3 and P10 was narrow.

Phage	Mt1B1_P3	Mt1B1_P10	Mt1B1_P17	vB_efoS_Str1	vB_efoP_Str2	vB_efoS_Str6
Host strain	<i>E.coli</i> Mt1B1	<i>E.coli</i> Mt1B1	<i>E.coli</i> Mt1B1	<i>E.faecalis</i> KB1	<i>E.faecalis</i> KB1	<i>E.faecalis</i> KB1
Family	<i>Podoviridae</i>	<i>Podoviridae</i>	<i>Myoviridae</i>	<i>Siphoviridae</i>	<i>Podoviridae</i>	<i>Siphoviridae</i>
Genus	<i>Teseptimavirus</i>	<i>Zindervirus</i>	unclassified	<i>Efquatrovirus</i>	<i>Saphexavirus</i>	<i>Copernicusvirus</i>
Genome size (kb)	40.3	45.4	151.2	41.6	18.1	57.7
Number of predicted ORFs	47	54	284	19	11	22
Genes unknown function (%)	40.4	64.3	94.7	72	59	74

106 Table 1

107 Further, we isolated three phages targeting *E. faecalis* KB1 (DSM 32036) from sewage water:
108 vB_EfaS_Strempe1 (short: Str1, DSM 110103), vB_EfaP_Strempe2 (Str2, DSM 110104),
109 vB_EfaS_Strempe6 (Str6, DSM 110108) and characterized them taxonomically and
110 functionally. Str1 and Str6 are members of the genus *Efquatrovirus* and *Saphexavirus*,
111 respectively, and show characteristic features of siphoviruses, whilst Str2 is a podovirus and

112 belongs to the *Copernicusvirus* genus (**Table 1**). In liquid culture, the phages inhibited *E.*
113 *faecalis* KB1 growth with different lysis profiles. All three phages added together mostly
114 resemble the lysis behavior of Str1 (**S1B Fig**). Str1 was highly strain-specific and only produced
115 visible plaques on *E. faecalis* KB1 when tested against 12 other *Enterococcus faecalis* and
116 *Enterococcus faecium* strains (**S1C Fig**). In contrast, Str6 exhibited the broadest host range,
117 targeting 5 out of 12 isolates, whereas Str2 lysed 3 out of 12 (**S1C Fig**). In addition, none of the
118 six phages infect the *Salmonella* strain used the following experiments.

119

120 **Phages specifically target their host strains within an *in vitro* bacterial community**

121 We next explored the effect of two phage cocktails ($3\Phi^{\text{Mt1B1}}$ and $3\Phi^{\text{KB1}}$) on a synthetic community
122 harboring *E. coli* Mt1B1 and *E. faecalis* KB1 *in vitro*. To this end, we added *E. coli* Mt1B1 and
123 *E. muris* JM-40 (DSM 28560) to the OMM¹² community (19, 25) (**S2A Fig**). The latter is a
124 secondary bile acid producer, which is a gut microbiota function lacking in the original OMM¹²
125 community. The 14 community members (OMM¹⁴) were added at equal ratios (OD₆₀₀) to
126 anaerobic media (AF medium, (20)) and diluted (1:100) every 24 h in batch culture. On day
127 three, 12 h after dilution, phages were introduced into the batch culture with a rough multiplicity
128 of infection (MOI) of 0.01 and incubation was prolonged for three days with dilution every 24
129 h (**Fig 1A**).

130 A significant drop in *E. coli* CFUs was observed 36h after phage cocktails treatment, followed
131 by an increase of *E. coli* density after 60 h (**Fig 1B**). *E. faecalis* levels in cultures treated with
132 phages also dropped significantly by approximately two orders of magnitude below control
133 levels after 36 h, also resulting in a regrowth after 60 h (**Fig 1C**). All phage titers increased after
134 36 h, coinciding with the drop in their host bacterial populations (**Fig 1D**). Furthermore, phages
135 were also tracked by specific qPCR, revealing that all three *E. coli* phages as well as *E. faecalis*
136 phages Str1 and Str2 replicate in the batch culture context (**S1D Fig**), whereas phage Str6
137 becomes undetectable after 60 h (**S1E Fig**).

138 The community composition was monitored by qPCR and remained stable over six days and
139 between the replicates (**Fig 1E, S1F Fig**). The species *E. coli* and *Blautia coccoides* YL58
140 dominated the communities in absolute abundances as 16S rRNA copies per ml culture, as
141 previously observed (19-21, 26). All strains but *Bifidobacterium animalis* YL2, *Acutalibacter*
142 *muris* KB18 and *Limosilactobacillus reuteri* I49 were detected and showed minimal changes in
143 their absolute abundance before and after phage treatment (**Fig 1E**). The overall stability of the
144 OMM¹² community members was not affected by the addition of either of the two phage
145 cocktails (**Fig 1E, S1F Fig**) suggesting that these phages can be used as strain-specific tools for
146 community manipulation.

147

148 ***E. coli* Mt1B1 and *E. faecalis* KB1 are specifically targeted by phage-cocktails in 149 gnotobiotic OMM¹⁴ mice**

150 Next, we investigated effects of the phage cocktails ($3\Phi^{\text{Mt1B1}}$ and $3\Phi^{\text{KB1}}$) on their host bacteria *in*
151 *vivo*. To this end, we established a stable colony of gnotobiotic OMM¹⁴ mice. Twelve out of
152 the 14 bacteria colonized the mouse gut in a stable manner over several generations, as
153 quantified in feces by qPCR (**S2B Fig**). *B. longum* subsp. *animalis* YL2 and *A. muris* KB18

154 were not detected, as previously shown in OMM¹² mice (24, 26); these strains either do not
155 colonize or fecal levels are below the detection limit of the qPCR.

156 Using the OMM¹⁴ mouse model, we studied the microbial community composition in response
157 to a single oral challenge of 3Φ^{Mt1B1} or 3Φ^{KB1} (1 x 10⁷ PFU of each phage in 100μl PBS or only
158 PBS as control without phages) in OMM¹⁴ mice (n = 4-6, **Fig 2A**). Absolute abundances of the
159 targeted bacteria and their phages in the feces was monitored on day 1 throughout 4 and day 7
160 post phage challenge (p.c.) via strain- and phage-specific qPCR. The treatment with 3Φ^{Mt1B1}
161 significantly reduced *E. coli* Mt1B1 loads on day 1-4, but strain 16S rRNA gene copy numbers
162 had reached again basal levels by day 7 (**Fig 2C**). The reduction of *E. faecalis* KB1 loads was
163 more pronounced at day 2 p.c. in mice treated with 3Φ^{KB1}, but the population also recovered by
164 day 7 p.c. (**Fig 2D**). The absolute abundances of the 12 other OMM members were not
165 significantly affected by phage administration (**Fig 2E; S3A Fig**) and remains more stable
166 compared to the batch culture.

167 Total phage levels determined as PFU per g feces were comparable for 3Φ^{Mt1B1} and 3Φ^{KB1},
168 reaching a maximum on day 1 p.c. with approximately 10⁷ PFU/g feces, followed by stable
169 levels between 10⁵ PFU/g feces -10⁶ PFU/g feces until day 7 p.c. (**Fig 2B**). In contrast to the
170 batch culture, qPCR on the feces revealed that only one of the three *E. coli* phages (phage P10)
171 was detectable at high levels in the feces (**S3B Fig**). Levels of phage P10 remained stable over
172 time at approximately 10⁸ copies/g feces, whereas phage P3 was only detectable on day 1 and
173 2 p.c. and then decreased below the detection limit of the qPCR assay. Phage P17 was also only
174 detectable at early time points in half of the mice (3 out of 6) at very low abundances (10⁵
175 copies/g feces - 10⁶ copies/g feces), close to the detection limit of the qPCR. On the other hand,
176 all three *E. faecalis* phages were detectable in feces via qPCR until day 7 of the experiment
177 (**S3C Fig**). Str2 and Str6 were highly abundant (10⁷ copies/g feces - 10⁹ copies/g feces), whilst
178 abundances of Str1 was lower but still above the detection limit in most of the mice.

179 To investigate if phage treatment causes inflammatory changes in the gut of treated mice, we
180 quantified fecal levels of lipocalin-2 (LCN2), an inflammation marker (zit) by ELISA. No
181 changes in LCN2 levels were observed over time or between the treatment groups (data not
182 shown).

183 Additionally, we also quantified short-chain fatty acid (SCFA) levels in feces over the course
184 of the experiment in order to assess potential collateral effects of the phage treatments on bile
185 acid metabolism (**S4 Fig**). For all measured SCFAs (2-Methylbutyric acid, Acetic acid, Butyric
186 acid, Isobutyric acid, Isovaleric acid, Lactic acid, Propionic acid, Valeric acid), no difference
187 was observed in treatment versus control groups.

188

189 **Phage cocktails targeting *E. coli* and *E. faecalis* leads to decreased colonization resistance 190 of OMM¹⁴ mice against *S. Tm***

191 To test the effect of phages on colonization resistance, we used an avirulent *Salmonella enterica*
192 serovar Typhimurium strain (*S. Tm*^{avir}), which colonizes the gut but does not induce
193 inflammation due to the lack of functional type III secretion systems 1 and 2 (19). OMM¹⁴ mice
194 (n = 6-8) were orally infected with *S. Tm*^{avir} (1x10⁷ CFU) directly followed by either the 3Φ^{Mt1B1}
195 or 3Φ^{KB1} phage cocktail (1x10⁷ PFU of each phage in PBS) or PBS control without phage (**Fig
196 3A**). Fecal samples were collected one and two days post infection (p. i.) with *S. Tm*⁻. As

197 confirmed in the previous experiment, *E. coli* Mt1B1 and *E. faecalis* KB1 loads significantly
198 decreased at day one p.c. by about one (*E. coli*) and two (*E. faecalis*) orders of magnitude (**Fig**
199 **3B** and **3C**). Phages were detectable in the gut for two days, with loads ranging between 4.2×10^4
200 PFU/g feces and 7.07×10^7 PFU/g feces. (**Fig 3D**). *S. Tm* loads on day one p.i. showed no
201 difference between the control group and any of the phage treatment groups (**Fig 3E** and **3F**).
202 Strikingly, at day two p. i., *S. Tm* loads were significantly increased in mice treated with phage
203 cocktails compared to the control groups (**Fig 3E**). This was more pronounced in the case of
204 mice treated with $3\Phi^{KB1}$, in which the *E. faecalis*-specific cocktail was associated with an
205 increase in *S. Tm* loads by two orders of magnitude (**Fig 3F**).

206 We next tested if phages which do not amplify in OMM¹⁴ mice due to the lack of host strains
207 would alter the susceptibility to *S. Tm* infection. We gavaged OMM¹⁴ mice with either a single
208 phage strain (vB_SauP_EBHT, 1×10^7 PFU in 100 μ L PBS), targeting *Staphylococcus aureus*
209 (strain EMRSA-15) or 100 μ L PBS and infected them with *S. Tm*^{avir} (**S5A Fig**). We had verified
210 previously that vB_SauP_EBHT did not target any of the OMM¹⁴ strains *in vitro*. No significant
211 difference in *S. Tm*^{avir} loads were observed between the control group ($p = 0.42$) and those
212 treated with phage vB_SauP_EBHT (**S5B Fig**), suggesting that phage treatment *per se* does not
213 alter colonization resistance. Phage loads were determined via spot assays on *S. aureus*, but
214 were only detectable in low numbers at day 1 p.c. (**S5E Fig**).
215

216 **Treatment with phages targeting *E. faecalis* KB1 facilitates development of *S. Tm*-induced 217 colitis in OMM¹⁴ mice**

218 The observed results proposed to test whether phage-mediated disruption of colonization
219 resistance in OMM¹⁴ mice would also enhance symptoms of *S. Tm*-induced colitis. Therefore,
220 OMM¹⁴ mice were infected with *S. Tm*^{wt} (1×10^7 CFU) and additionally with either $3\Phi^{Mt1B1}$ or
221 $3\Phi^{KB1}$ phage cocktail (1×10^7 PFU of each phage in PBS or PBS control; **Fig 4A**). Fecal samples
222 were collected one and two days post infection (p. i.). Phage levels were comparable to the
223 previous *in vivo* experiments and stayed stable until day four p. c. despite the inflammation in
224 the gut (**S6A Fig**). In this experiment, loads of *E. coli* Mt1B1 significantly decreased at day one
225 p. c. and *E. faecalis* KB1 loads were significantly decreased at day 1- 4 p. c. (**Fig 4B** and **4C**).
226 *S. Tm*^{wt} loads showed a significant increase on day two and three p. c. (**Fig 4D**) in the group
227 treated with *E. faecalis* $3\Phi^{KB1}$ phage cocktail compared to the control group. Strikingly, in this
228 group, *S. Tm* inflammation was enhanced as determined by increased fecal lipocalin-2 levels at
229 day 3 p. i.. No difference was found at day 4 p. i. both in lipocalin-2 levels and cecal histology
230 (**Fig 4E** and **4F**). In contrast, no change in *S. Tm* inflammation was observed in the group
231 treated with *E. coli* $3\Phi^{Mt1B1}$ phage cocktail. The absolute abundances of all members of the
232 OMM¹⁴ consortium as well as the phages was determined by qPCR (**S6C Fig**). In general,
233 overall bacterial levels were stable until day three, followed by a strong variation in abundance
234 in all treatment groups on day four (**S6C Fig**). This effect is likely due to coinciding severe *S.*
235 *Tm*-induced gut inflammation. In conclusion, we verified that phage treatment accelerates not
236 only pathogen invasion but also disease onset in case of the $3\Phi^{KB1}$ phage cocktail.
237

238 **Phage cocktails impair colonization resistance independently of changing abundance of 239 protective bacteria**

240 To investigate whether phages could also have a long-term impact on colonization resistance,
241 we inoculated groups of OMM¹⁴ mice with 3Φ^{Mt1B1} or 3Φ^{KB1} phage cocktails (or PBS control)
242 and then infected them with *S. Tm*^{avir} (1x10⁷ CFU) on day seven p.c.. Fecal samples were
243 collected one and two days post infection (p. i.) (**Fig 5A**), where no significant differences in
244 *E. coli* Mt1B1 or *E. faecalis* KB1 loads were observed anymore between the groups (**Fig 5B**
245 and **5C**) but phages were still present at steady numbers in the feces (**Fig 5D**). Further, overall
246 OMM¹⁴ composition had reverted to the state before treatment (**S3A Fig**). Interestingly, *S.*
247 *Tm*^{avir} loads at day 8 and 9 p.c. (corresponding to day one and two p.i.) were significantly
248 increased in both phage-treated groups (**Fig 5E**). This suggests that phages can also impair
249 colonization resistance without detectable impact on their target bacteria or overall composition
250 of the microbiota.

251

252

253 Discussion

254 Phages are the most prevalent viruses in the gut (27, 28) and coexist with their host bacteria
255 over long periods (17). They play an important role in shaping composition, dynamics (29) and
256 evolution (30) of microbial communities (31). There is a growing recognition for the therapeutic
257 use of phages against intestinal colonization by multi-drug resistant strains and bacteria causally
258 involved in the pathogenesis of inflammatory bowel diseases (32). Nevertheless, the functional
259 impact of phages on bacterial communities is not fully understood. Using mice stably associated
260 with a community of 14 commensal bacterial species, we show that virulent phages targeting
261 specific strains in the community can impair colonization resistance and increase susceptibility
262 of mice to oral infection by a human intestinal pathogen.

263 Phage infection of *E. coli* and *E. faecalis* in OMM¹⁴ mice can be roughly divided into two
264 phases: A transient reduction of the bacterial target population in the acute infection phase (1-
265 4 days p.c.) paralleled by high initial phage loads. Thereafter, as the second phase, phages and
266 host bacteria co-existed until day 7 p. c.. Previous work demonstrated that co-existence is in
267 part explained by phage-inaccessible sites in the mucosa, which serve as a spatial refuge for
268 part of the host bacterial population (17). In addition, bacterial hosts differentially express genes
269 in the gut that foster phage-bacteria coexistence (33). Phage-specific qPCR analysis allowed us
270 to quantify individual phages. This revealed that the abundance of the three different phages in
271 each cocktail differed markedly in the feces. For example, *E. coli* phage P10 dominated at all
272 time points while loads of phage P3 and P17 decreased rapidly after inoculation below the limit
273 of detection. Interestingly, abundance of *E. faecalis* phages was also different, but all three
274 phages were detectable until seven days p. c.. Different abundances of phages may be due to
275 burst size, stability of the co-existence and perhaps selection of phage-resistant mutants, leading
276 to different abundances and abilities of the individual phages to infect and amplify.

277 Phage treatment impaired CR against *S. Tm* in the acute phage infection phase. CR in the
278 OMM¹² model is mediated by competition for substrates including C5/C6 sugars, oxygen and
279 electron acceptors for anaerobic respiration (21), and OMM¹² mice lacking *S. Tm* competitors
280 *E. coli* Mt1B1 or *E. faecalis* KB1 exhibit loss of CR. Thus, we reason that transient reduction
281 of these two species caused by phage treatment leads to a short-term increase in substrate
282 availability and weakening of the targeted strains opening a window for pathogen invasion. In

283 support of this idea, the degree of reduction of the target population in the acute phase equals
284 the increase in pathogen loads. Besides phage-induced changes in the microbiota, antibiotic-
285 mediated disruption of the microbiota transiently increases levels of free sugars which can be
286 exploited by pathogens (34). Moreover it was shown, that a high-fat diet increasing bile acid
287 release and microbiota changes can also facilitate pathogen invasion (5).

288 Surprisingly, mice also displayed impaired CR at day 7 post phage challenge, when phages and
289 their target strains stably co-existed in the gut. This hints to mechanisms also acting
290 independently on the reduction of the loads of competing bacteria. Phages may decrease the
291 target population locally, enabling *S. Tm* to invade. In addition, the presence of phages might
292 induce transcriptional changes of the host strains leading to increased resistance against phage
293 infection. These may include expression of anti-phage systems and reprogramming of bacterial
294 metabolism (35) and phage receptors (33). Such potential changes may directly or indirectly
295 affect CR against *S. Tm*. Further work is needed to clarify this interrelation.

296 Using a wildtype *S. Tm* strain which triggers gut inflammation within 3 days of infection in
297 gnotobiotic mice (21), we observed impaired CR and a faster onset of gut inflammation when
298 mice were treated with the *E. faecalis* cocktail $3\Phi^{KB1}$. However, the $3\Phi^{Mt1B1}$ cocktail had no
299 effect on the course of *S. Tm*^{WT} infection. This differential effect of phages on avirulent and the
300 wildtype *S. Tm* infection might be due to utilization of different niches of both, *S. Tm* and *E.*
301 *coli* in the normal versus inflamed intestine (36).

302 An important selling point of phage therapy is that phage cocktails act in species-specific
303 manner and do not disrupt the overall (bacterial) microbiome composition (10, 37, 38). In our
304 work, we confirm that the phage cocktails specifically targeting *E. coli* Mt1B1 and *E. faecalis*
305 KB1 do not affect the overall bacterial community structure. Even though, we demonstrate that
306 phage cocktails can create a window of opportunity for pathogen invasion, in this case human
307 pathogenic *S. Tm*, if commensals relevant for mediating CR are specifically targeted. Based on
308 our data, we reason that one possible future application of phage cocktails is to facilitate strain-
309 replacement strategies – and mediate exchange of harmful bacteria by beneficial strains in the
310 human microbiome (39, 40).

311 In conclusion, we show that phage cocktails targeting strains that are functionally important for
312 mediating protection against pathogens can open up niches for pathogens (and potentially also
313 non-pathogenic bacteria) to invade the gut. We reason that phage ingestion in conjunction with
314 pathogen contaminated food or water sources could facilitate pathogen invasion and may
315 therefore be risk factors of human *Salmonella* infection. Coliphage content in water ranges from
316 8×10^4 PFU/100mL in wastewater to 30 PFU/100mL for river source waters (41), which might
317 be enough to target protective bacteria in the gut. Eventually, future work will be needed to
318 clarify if therapeutic application of phage cocktails against multidrug resistant *E. coli* or *E.*
319 *faecalis* strains may also impair CR in the human host and should therefore be handled with
320 caution.

321 **Methods**

322

323 **Strains and culture conditions**

324 The following strains were used in this study: *Enterococcus faecalis* KB1 (DSM 32036),
325 *Bifidobacterium animalis* YL2 (DSM 26074), *Acutalibacter muris* KB18 (DSM 26090),
326 *Muribaculum intestinale* YL27 (DSM 28989), *Flavonifractor plautii* YL31 (DSM 26117),
327 *Enterocloster clostridioformis* YL32 (DSM 26114), *Akkermansia muciniphila* YL44 (DSM
328 26127), *Turicimonas muris* YL45 (DSM 26109), *Clostridium innocuum* I46 (DSM 26113),
329 *Bacteroides caecimuris* I48 (DSM 26085), *Limosilactobacillus reuteri* I49 (DSM 32035),
330 *Blautia coccoides* YL58 (DSM 26115), *Escherichia coli* Mt1B1 (DSM 28618) (26), *Extibacter*
331 *muris* JM40 (DSM 28560) (25), *S. Tm*^{wt} SL1344 (SB300) (42), *S. Tm*^{avir} M2707 (43),
332 *Staphylococcus aureus* RG2 (DSM 104437).

333 OMM¹⁴ cultures were prepared from individual glycerol cryostocks in a 10 ml culture and
334 subculture in cell culture flasks (flask T25, Sarstedt) previous to all *in vitro* experiments.
335 Cultures were incubated at 37°C without shaking under strictly anaerobic conditions (gas
336 atmosphere 7% H₂, 10% CO₂, 83% N₂). OMM¹⁴ bacterial cultures were grown in anaerobic
337 medium (AF medium, : 18 g.l⁻¹ brain-heart infusion (Oxoid), 15 g.l⁻¹ trypticase soy broth
338 (Oxoid), 5 g.l⁻¹ yeast extract, 2.5 g.l⁻¹ K₂HPO₄, 1 mg.l⁻¹ haemin, 0.5 g.l⁻¹ D-glucose, 0.5 mg.l⁻¹
339 menadione, 3% heat-inactivated fetal calf serum, 0.25 g.l⁻¹ cysteine-HCl x H₂O).

340 For mouse infection experiments, *S. Tm* strains were grown on MacConkey agar plates (Oxoid)
341 containing streptomycin (50 µg/ml) at 37 °C. One colony was re-suspended in 3 ml LB
342 containing 0.3 M NaCl and grown 12 h at 37 °C on a wheel rotor. A subculture (1:20 dilution)
343 was prepared in LB with 0.3 M NaCl and incubated for 4 h. Bacteria were washed in ice-cold
344 sterile PBS, pelleted and re-suspended in PBS for gavage.

345

346 **Spot assays**

347 1 ml of an exponentially growing bacterial culture, containing the phage host, was applied on
348 an EBU agar plate, containing Evans Blue (1%) and Fluorescein sodium salt (1%) to visualize
349 bacterial lysis, which is indicated by a color change to dark green. Excess liquid was removed
350 and the plate was dried under the laminar airflow cabinet for 15 minutes. Phage lysates were
351 serially diluted in sterile PBS and 5 µl of each dilution was spotted on the bacterial lawn. The
352 plate was incubated over night at 37°C. The next day, clear plaques and lysis of the bacteria
353 could be detected. Plaques were counted to quantify plaque forming units (PFU).

354

355 **Isolation of *E. faecalis* KB1 phages from sewage water**

356 For isolation of phages specific for *Enterococcus faecalis* KB1, sewage water from different
357 sources was filtered (0.22 µm) and mixed with an equal volume of 2 x LB media. Next, bacterial
358 overnight culture was added with a final dilution of 1/100 and incubated overnight at 37°C
359 without shaking. The next day, the cultures were centrifuged (6,000 x g, 10 min), filtered (0.22
360 µm) and spotted in serial dilution on a lawn of *E. faecalis* KB1 on EBU plates followed by
361 another incubation at 37 °C overnight. If clear plaques were visible, individual plaques were

362 picked and diluted in 100 μ l SM buffer (100 mM NaCl, 8.1 mM MgSO₄ x H₂O, 50 mM Tris-HCL (pH 7.5)), added to a fresh bacterial subculture in 10 ml LB medium and incubated overnight. Centrifugation and filtration of this culture resulted in a sterile phage suspension which was stored at 4°C and used for the *in vitro* and *in vivo* experiments.

366

367 **Generation of phage cocktails**

368 100 μ l of purified and sterile phage suspension was added to 10 ml of LB media and incubated
369 with 100 μ l of overnight culture of their respective bacterial host overnight at 37°C. The next
370 day, the cultures were centrifuged (6,000 x g, 10 min), filtered (0.22 μ m) and spotted in serial
371 dilution on a lawn of their respective bacterial host on EBU plates followed by another
372 incubation at 37°C overnight. The next day, plaque forming units were calculated for the phage
373 suspensions ($\frac{\text{number of plaques} * \text{dilution}}{\text{used phage lysate (ml)}}$) and the phages were mixed together in a concentration
374 of 1×10^7 PFU/100 μ l each. The following phages were used in this study: Mt1B1_P3,
375 Mt1B1_P10, Mt1B1_P17 (17), vB_efoS_Str1 (vB_EfaS_Strempe1, DSM 110103),
376 vB_efoP_Str2 (vB_EfaP_Strempe1, DSM 110104), vB_efoS_Str6 (vB_EfaS_Strempe1,
377 DSM 110108), vB_SauP_EBHT (DSM 26856).

378

379 **Phage genome sequencing and analysis**

380 The three phages targeting *E. coli* Mt1B1 were sequenced and analyzed as described previously
381 (17). Shortly, sequencing was performed using Illumina MiSeq Nano. Assembly was performed
382 using a workflow implemented in Galaxy-Institut Pasteur and phage termini were determined
383 by PhageTerm. The three *E. faecalis* KB1 phages were also sequenced using Illumina MiSeq
384 Nano and assembled with SPAdes (3.12.0) (44). Annotation was performed using PROKKA
385 (45) and taxonomic classification was performed using VICTOR (46) as previously described
386 (47).

387

388 **Growth measurements**

389 Bacterial growth was measured in 96 well plates (Sarstedt TC-cellculture plate) using an
390 Epoch2 plate reader (GenTech). Inocula were prepared from an overnight culture and
391 subculture and diluted in AF medium (20) to 0.01 OD₆₀₀. To determine phage growth and
392 bacterial lysis, 150 μ l of bacterial culture was added to each well, followed by either 10 μ l of
393 PBS as a control or 10 μ l of sterile phage lysate with a defined concentration of active phages
394 (PFU/ml), resulting in a MOI of 0.01. During continuous measurements, the plate was heated
395 inside the reader to 37°C and a 30 second double orbital shaking step was performed prior to
396 every measurement. Measurements took place every 15 minutes for a duration of 20 hours in
397 total.

398

399 **OMM¹⁴ community cultures**

400 OMM¹⁴ communities were cultured as previously described (20). Shortly, monoculture inocula
401 were prepared from an overnight culture and subculture and were diluted to OD₆₀₀ 0.1 in AF

402 medium. Following, the community inoculum with equivalent ratios of all 14 strains was
403 generated from this dilution. The inoculum was distributed to 24 well plates, thereby diluting
404 the inoculum 1:10 with 0.9 ml AF medium, resulting in a starting OD₆₀₀ of 0.01 (time = 0h).
405 24-well plates were incubated at 37°C without shaking under anaerobic conditions. Every 24 h,
406 samples were taken for qPCR analysis and spot assays, and cultures were diluted 1:100 in AF
407 medium. Phages were added to the community 12h after the third dilution, in a concentration
408 of 1*10⁶ PFU per phage in 10 µl PBS.

409

410 **Animal experiments**

411 Germ-free mice were inoculated with OMM¹² cryostock mixtures as described (26) and
412 individual frozen stocks of *E. muris* and *E. coli* Mt1B1. Stocks were thawed in 1% Virkon S
413 (V.P. Produkte) disinfectant solution and used for inoculation of germ-free C57Bl/6 mice in a
414 flexible film isolator. Mice were inoculated twice (72 h apart) with the bacterial mixtures and
415 the two single stocks by gavage (50 µl orally, 100 µl rectally). Mice were housed and bred under
416 germfree conditions in flexible film isolators (North Kent Plastic Cages). For experiments, mice
417 were transferred into isocages (IsoCage P system, Tecniplast). Mice were supplied with
418 autoclaved ddH₂O and autoclaved Mouse-Breeding complete feed for mice (Ssniff) *ad libitum*.
419 For the following experiments, only mice starting from generation F1 were used, to ensure
420 stable colonization of the consortium.

421 For all experiments, female and male mice between 6-20 weeks were used and animals were
422 assigned to experimental groups to match sex and age. Mice were kept in groups of 2-6
423 mice/cage during the experiment. All animals were scored twice daily for their health status.
424 Phage cocktails containing the same concentration of phages as for the *in vitro* experiments
425 (10⁷ PFU per phage in 100 µl PBS) were administered by oral gavage. Mice were infected with
426 *S. Tm* by oral gavage with 50 µl of bacterial suspension (approximately 5x10⁷ CFU). All mice
427 were sacrificed by cervical dislocation. Feces and cecal content were weighed and dissolved in
428 500 µl sterile PBS and *S. Tm* and *E. coli* Mt1B1 loads were determined by plating in several
429 dilutions on MacConkey agar (Oxoid) supplemented with respective antibiotics (vancomycin
430 7.5 µg/ml for *E. coli*, streptomycin 50 µg/ml for *S. Tm*). *E. faecalis* KB1 loads were determined
431 by plating in several dilutions on BHI agar (Oxoid), supplemented with polymycin B 50 µg/ml.
432 100 µl of dissolved intestinal content were sterile filtered using Centrifuge Tube Filter (0.22
433 µm, Costar Spin-X) and spotted in serial dilutions in PBS on a lawn of *E. coli* and *E. faecalis*
434 on EBU agar plates to determine the phage loads. Lipocalin-2 was quantified from supernatant
435 of frozen cecal content. For metabolomics, samples were directly snap frozen in liquid N₂ and
436 stored at -80°C until further processing. Samples for DNA extraction were stored at -20°C after
437 weighing.

438

439 **DNA extraction from intestinal content**

440 gDNA extraction was performed using a phenol-chloroform based protocol as described
441 previously (48). Briefly, fecal pellet or cecal content was resuspended in 500 µl extraction
442 buffer (200 mM Tris-HCl, 200 mM NaCl, 20 mM EDTA in ddH₂O, pH 8, autoclaved), 210 µl
443 20 % SDS and 500 µl phenol:chloroform:isoamylalcohol (25:24:1, pH 7.9). Furthermore, 500 µl
444 of 0.1 mm-diameter zirconia/silica beads (Roth) were added. Bacterial cells were lysed with a

445 bead beater (TissueLyser LT, Qiagen) for 4 min, 50 Hz. After centrifugation (14,000 x g, 5 min,
446 RT), the aqueous phase was transferred into a new tube, 500 µl
447 phenol:chloroform:isoamylalcohol (25:24:1, pH 7.9) were added and again spun down. The
448 resulting aqueous phase was gently mixed with 1 ml 96 % ethanol and 50 µl of 3 M sodium
449 acetate by inverting. After centrifugation (30 min, 14,000 x g, 4 °C), the supernatant was
450 discarded and the gDNA pellet was washed with 500 µl ice-cold 70 % ethanol and again
451 centrifuged (14,000 x g, 4 °C; 15 min). The resulting gDNA pellet was resuspended in 100 µl
452 Tris-HCL pH 8.0. Subsequently, gDNA was purified using the NucleoSpin gDNA clean-up kit
453 (Macherey-Nagel) and stored at -20°C.

454

455 **Quantitative PCR for bacteria and phages**

456 Quantitative PCR was performed as described previously (for the OMM¹² strains and *E. coli*
457 Mt1B1 see (19), for *E. muris* JM40 see (25)). Standard curves using linearized plasmids
458 containing the 16S rRNA gene sequence of the individual strains were used for absolute
459 quantification of 16S rRNA gene copy numbers of individual strains.

460 Probe and primer design for the phages was done using the software PrimerExpress. 1500 bp
461 of either the phage tail fiber gene or the phage major capsid protein gene were used as a template
462 gene instead of the bacterial 16S rRNA gene to design probes, primers and plasmids (**Table**
463 **S1**). Absolute quantification was conducted as for the bacterial qPCR (19).

464

465 **Lipocalin-2 quantification**

466 Lipocalin-2 levels in feces and cecal content were determined by an enzyme-linked
467 immunosorbent assay (ELISA) kit and protocol from R&D Systems (DY1857, Minneapolis,
468 US), following manufacturer's instructions. Absorbance was measured at OD₄₀₅.

469

470 **Targeted short chain fatty acid (SCFA) measurement**

471 Feces and gut content (approximately 20 mg) for metabolomic profiling were freshly sampled,
472 weighed in a 2 ml bead beater tube (CKMix 2 mL, Bertin Technologies, Montigny-le-
473 Bretonneux, France) filled with ceramic beads (1.4 mm and 2.8 mm ceramic beads i.d.) and
474 immediately snap frozen in liquid nitrogen. The following procedure and measurement was
475 performed at the BayBioMS (TU Munich). 1 mL methanol was added and the sample was
476 homogenized by bead beating using a bead beater (Precellys Evolution, Bertin Technologies)
477 supplied with a Cryolys cooling module (Bertin Technologies, cooled with liquid nitrogen) 3
478 times each for 20 seconds with 15 seconds breaks in between, at a speed of 10.000 rpm. After
479 centrifugation of the suspension (10 min, 8000 rpm, 10°C) using an Eppendorf Centrifuge
480 5415R (Eppendorf, Hamburg, Germany), the 3-NPH method was used for the quantitation of
481 SCFAs (49). Briefly, 40 µL of the fecal extract and 15 µL of isotopically labeled standards (ca
482 50 µM) were mixed with 20 µL 120 mM EDC HCl-6% pyridine-solution and 20 µL of 200
483 mM 3-NPH HCL solution. After 30 min at 40°C and shaking at 1000 rpm using an Eppendorf
484 Thermomix (Eppendorf, Hamburg, Germany), 900 µL acetonitrile/water (50/50, v/v) was
485 added. After centrifugation at 13000 U/min for 2 min the clear supernatant was used for

486 analysis. The measurement was performed using a QTRAP 5500 triple quadrupole mass
487 spectrometer (Sciex, Darmstadt, Germany) coupled to an ExionLC AD (Sciex, Darmstadt, Germany)
488 ultra high performance liquid chromatography system. The electrospray voltage was
489 set to -4500 V, curtain gas to 35 psi, ion source gas 1 to 55, ion source gas 2 to 65 and the
490 temperature to 500°C. The MRM-parameters were optimized using commercially available
491 standards for the SCFAs. The chromatographic separation was performed on a 100 × 2.1 mm,
492 100 Å, 1.7 µm, Kinetex C18 column (Phenomenex, Aschaffenburg, Germany) column with
493 0.1% formic acid (eluent A) and 0.1% formic acid in acetonitrile (eluent B) as elution solvents.
494 An injection volume of 1 µL and a flow rate of 0.4 mL/min was used. The gradient elution
495 started at 23% B which was held for 3 min, afterward the concentration was increased to 30%
496 B at 4 min, with another increase to 40% B at 6.5 min, at 7 min 100% B was used which was
497 hold for 1 min, at 8.5 min the column was equilibrated at starting conditions. The column oven
498 was set to 40°C and the autosampler to 15°C. Data aquisition and instrumental control were
499 performed with Analyst 1.7 software (Sciex, Darmstadt, Germany).

500

501 **Hematoxylin and eosin staining (HE staining) and histopathological scoring**

502 HE staining was performed as described previously (Herp et al., 2019). Cecal tissue, directly
503 frozen in O.C.T, was cut in 5 µm sections using a cryotome (Leica) and mounted onto
504 Superfrost Plus glass slides (Hartenstein). Sections were dried o/n. and fixed in Wollman
505 solution (95 % ethanol, 5 % acetic acid) for 30 s, washed in flowing tap water (1 min) and rinsed
506 in dH₂O. Afterwards, slides were incubated in Vectors's Hämalaun (Roth) for 20 min, washed
507 in flowing tap water (5 min), dipped in de-staining solution (70 % ethanol with 1 % HCl) once,
508 washed again in flowing tap water (5 min) and rinsed in dH₂O with subsequent rinses in 70 %
509 and 90 % ethanol. Slides were then dipped for 15 s in alcoholic eosin (90 % ethanol) with
510 Phloxin (Sigma-Aldrich), rinsed in dH₂O followed by dehydration in 90 % ethanol, 100 %
511 ethanol and xylene. Sections were directly mounted with Rotimount (Roth) and dried
512 thoroughly.

513 Histopathological scoring of cecal tissue was performed as described previously (50).
514 Submucosal edema (0-3), infiltration of polymorphonuclear neutrophils (PMNs) (0-4), loss of
515 goblet cells (0-3) and epithelial damage (0-3) was evaluated and all individual scores were
516 summed up to give a final pathology score: 0-3 no inflammation; 4-8 mild inflammation; 9-13
517 profound inflammation.

518

519 **Generation of a 16S rRNA gene-based phylogenetic tree**

520 The genomes of the twelve strains of the OMM¹² consortium (51) were accessed via
521 DDBJ/ENA/GenBank using the following accession numbers: CP022712.1, NHMR02000001-
522 NHMR02000002, CP021422.1, CP021421.1, NHMQ01000001-NHMQ01000005,
523 NHTR01000001-NHTR01000016, CP021420.1, NHMP01000001-NHMP01000020,
524 CP022722.1, NHMU01000001-NHMU01000019, NHMT01000001-NHMT01000003,
525 CP022713.1, CP028714, KR364761.1 and annotated using Prokka (default settings) (52). The
526 16S rRNA sequences of all strains were obtained. These rRNA FASTA sequences were
527 uploaded to the SINA Aligner v1.2.11 (53) to align these sequences with minimum 95% identity
528 against the SILVA database. By this, a phylogenetic tree based on RAxML, GTR Model and

529 Gamma rate model for likelihood was reconstructed. Sequences with less than 90% identity
530 were rejected. The obtained tree was rooted using *midpoint.root()* in the phytools package (54)
531 in R and visualized using iTOL online (55).

532

533 **Generation of 16s rRNA gene based tree different *Enterococcus* strains**

534 16S rRNA gene sequences of all tested *Enterococcus* strains and selected reference type strains
535 of the family *Enterococcaceae* were downloaded from NCBI and aligned with Mega-X Version
536 10.1.5. A Maximum Likelihood tree was constructed using the Tamura-Nei model and the
537 Nearest-Neighbor-Interchange method. The tree was exported in Newick tree format and
538 annotation was done using iTOL online (55).

539

540 **Statistical analysis**

541 Statistical details for each experiment are indicated in the figure legends. Mann-Whitney U test
542 and Kruskal-Wallis test were performed using the software GraphPad Prism version 5.01 for
543 Windows (GraphPad Software, La Jolla California USA, www.graphpad.com). P values of less
544 than 0.05 were considered as statistically significant and only those are indicated in the figures
545 (*P<0.05, **P<0.01, ***P<0.001).

546 **Acknowledgements**

547 This research was supported by Collaborative Research Center 1371 funded by the German
548 Research Foundation (project number 395357507, P14, Z01), the European Research Council
549 (EVOGUTHEALTH; grant no. 865615), DFG-ANR project PhaStGut (STE 1971/11-1), the
550 DFG Priority Programme SPP2330, the German Center for Infection Research (DZIF) and the
551 Center for Gastrointestinal Microbiome Research (CEGIMIR). We are grateful to Saib Hussain
552 and the Germ-free Rodent Facility of the Max von Pettenkofer Institute, LMU Munich for
553 excellent technical support.

554

555 **Author contributions**

556 Conceived and designed the experiments: B.S., A.v.S; Performed the experiments: A.v.S.,
557 A.S.W., M.S.S., E.W., K.K.; Analyzed the data: A.v.S., K.K., M.G.; B.S. Contributed
558 materials/analysis tools: L.D., E.W., T.C.; Secured funding: B.S.; A.v.S. coordinated the project
559 and wrote the original draft; all authors reviewed and edited the draft manuscript.
560 Correspondence and requests for materials should be addressed to B.S..

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589 **References**

- 590 1. Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in
591 the Body. *PLoS Biol.* 2016;14(8):e1002533.
- 592 2. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal
593 pathogens. *Nat Rev Immunol.* 2013;13(11):790-801.
- 594 3. Kim S, Covington A, Pamer EG. The intestinal microbiota: Antibiotics, colonization resistance,
595 and enteric pathogens. *Immunol Rev.* 2017;279(1):90-105.
- 596 4. Kreuzer M, Hardt WD. How Food Affects Colonization Resistance Against Enteropathogenic
597 Bacteria. *Annu Rev Microbiol.* 2020;74:787-813.
- 598 5. Wotzka SY, Kreuzer M, Maier L, Arnoldini M, Nguyen BD, Brachmann AO, et al. *Escherichia*
599 *coli* limits *Salmonella Typhimurium* infections after diet shifts and fat-mediated microbiota
600 perturbation in mice. *Nat Microbiol.* 2019;4(12):2164-74.
- 601 6. Rogers AWL, Tsolis RM, Baumler AJ. *Salmonella* versus the Microbiome. *Microbiol Mol Biol*
602 Rev. 2021;85(1).
- 603 7. Alavi S, Mitchell JD, Cho JY, Liu R, Macbeth JC, Hsiao A. Interpersonal Gut Microbiome
604 Variation Drives Susceptibility and Resistance to Cholera Infection. *Cell.* 2020;181(7):1533-46 e13.
- 605 8. Osbelt L, Wende M, Almasi E, Derksen E, Muthukumarasamy U, Lesker TR, et al. *Klebsiella*
606 *oxytoca* causes colonization resistance against multidrug-resistant *K. pneumoniae* in the gut via
607 cooperative carbohydrate competition. *Cell Host Microbe.* 2021;29(11):1663-79 e7.
- 608 9. Dzunkova M, Low SJ, Daly JN, Deng L, Rinke C, Hugenholtz P. Defining the human gut host-
609 phage network through single-cell viral tagging. *Nat Microbiol.* 2019;4(12):2192-203.
- 610 10. Reyes A, Semenkovich NP, Whiteson K, Rohwer F, Gordon JI. Going viral: next-generation
611 sequencing applied to phage populations in the human gut. *Nat Rev Microbiol.* 2012;10(9):607-17.
- 612 11. Hsu BB, Gibson TE, Yeliseyev V, Liu Q, Lyon L, Bry L, et al. Dynamic Modulation of the Gut
613 Microbiota and Metabolome by Bacteriophages in a Mouse Model. *Cell Host Microbe.*
614 2019;25(6):803-14 e5.
- 615 12. Reyes A, Wu M, McNulty NP, Rohwer FL, Gordon JI. Gnotobiotic mouse model of phage-
616 bacterial host dynamics in the human gut. *Proc Natl Acad Sci U S A.* 2013;110(50):20236-41.
- 617 13. Howe A, Ringus DL, Williams RJ, Choo ZN, Greenwald SM, Owens SM, et al. Divergent
618 responses of viral and bacterial communities in the gut microbiome to dietary disturbances in mice.
619 *ISME J.* 2016;10(5):1217-27.
- 620 14. Boling L, Cuevas DA, Grasis JA, Kang HS, Knowles B, Levi K, et al. Dietary prophage inducers
621 and antimicrobials: toward landscaping the human gut microbiome. *Gut Microbes.* 2020;11(4):721-
622 34.
- 623 15. Oh JH, Alexander LM, Pan M, Schueler KL, Keller MP, Attie AD, et al. Dietary Fructose and
624 Microbiota-Derived Short-Chain Fatty Acids Promote Bacteriophage Production in the Gut Symbiont
625 *Lactobacillus reuteri*. *Cell Host Microbe.* 2019;25(2):273-84 e6.
- 626 16. Clooney AG, Sutton TDS, Shkoporov AN, Holohan RK, Daly KM, O'Regan O, et al. Whole-
627 Virome Analysis Sheds Light on Viral Dark Matter in Inflammatory Bowel Disease. *Cell Host Microbe.*
628 2019;26(6):764-78 e5.
- 629 17. Lourenco M, Chaffringeon L, Lamy-Besnier Q, Pedron T, Campagne P, Eberl C, et al. The
630 Spatial Heterogeneity of the Gut Limits Predation and Fosters Coexistence of Bacteria and
631 Bacteriophages. *Cell Host Microbe.* 2020;28(3):390-401 e5.
- 632 18. Gregory AC, Zablocki O, Zayed AA, Howell A, Bolduc B, Sullivan MB. The Gut Virome Database
633 Reveals Age-Dependent Patterns of Virome Diversity in the Human Gut. *Cell Host Microbe.*
634 2020;28(5):724-40 e8.
- 635 19. Brugiroux S, Beutler M, Pfann C, Garzetti D, Ruscheweyh HJ, Ring D, et al. Genome-guided
636 design of a defined mouse microbiota that confers colonization resistance against *Salmonella*
637 *enterica* serovar *Typhimurium*. *Nat Microbiol.* 2016;2:16215.

638 20. Weiss AS, Burrichter AG, Durai Raj AC, von Strempe A, Meng C, Kleigrewe K, et al. In vitro
639 interaction network of a synthetic gut bacterial community. *ISME J.* 2022;16(4):1095-109.

640 21. Eberl C, Weiss AS, Jochum LM, Durai Raj AC, Ring D, Hussain S, et al. *E. coli* enhance
641 colonization resistance against *Salmonella Typhimurium* by competing for galactitol, a context-
642 dependent limiting carbon source. *Cell Host Microbe.* 2021;29(11):1680-92 e7.

643 22. Armon R, Araujo R, Kott Y, Lucena F, Jofre J. Bacteriophages of enteric bacteria in drinking
644 water, comparison of their distribution in two countries. *J Appl Microbiol.* 1997;83(5):627-33.

645 23. Del Rio B, Sanchez-Llana E, Martinez N, Fernandez M, Ladero V, Alvarez MA. Isolation and
646 Characterization of *Enterococcus faecalis*-Infecting Bacteriophages From Different Cheese Types.
647 *Front Microbiol.* 2020;11:592172.

648 24. Afrizal Afrizal SAVJ, Thomas C. A. Hitch, Thomas Riedel, Marijana Basic, Atscharah Panyot,
649 Nicole Treichel, Fabian T. Hager, Ramona Brück, Erin Oi-Yan Wong, Alexandra von Strempe, Claudia
650 Eberl, Eva M. Buhl, Birte Abt, André Bleich, René Tolba, William W. Navarre, View ORCID
651 ProfileFabian Kiessling, Hans-Peter Horz, Natalia Torow, Vuk Cerovic, Bärbel Stecher, Till Strowig,
652 Jörg Overmann, Thomas Clavel. Enhanced cultured diversity of the mouse gut microbiota enables
653 custom-made synthetic communities. *bioRxiv.* 2022.

654 25. Streidl T, Karkossa I, Segura Munoz RR, Eberl C, Zaufel A, Plagge J, et al. The gut bacterium
655 *Extibacter muris* produces secondary bile acids and influences liver physiology in gnotobiotic mice.
656 *Gut Microbes.* 2021;13(1):1-21.

657 26. Eberl C, Ring D, Munch PC, Beutler M, Basic M, Slack EC, et al. Reproducible Colonization of
658 Germ-Free Mice With the Oligo-Mouse-Microbiota in Different Animal Facilities. *Front Microbiol.*
659 2019;10:2999.

660 27. Breitbart M, Haynes M, Kelley S, Angly F, Edwards RA, Felts B, et al. Viral diversity and
661 dynamics in an infant gut. *Res Microbiol.* 2008;159(5):367-73.

662 28. Guerin E, Hill C. Shining Light on Human Gut Bacteriophages. *Front Cell Infect Microbiol.*
663 2020;10:481.

664 29. Marbouth M, Thierry A, Millot GA, Koszul R. MetaHiC phage-bacteria infection network
665 reveals active cycling phages of the healthy human gut. *Elife.* 2021;10.

666 30. Silveira CB, Rohwer FL. Piggyback-the-Winner in host-associated microbial communities. *NPJ
667 Biofilms Microbiomes.* 2016;2:16010.

668 31. De Sordi L, Khanna V, Debarbieux L. The Gut Microbiota Facilitates Drifts in the Genetic
669 Diversity and Infectivity of Bacterial Viruses. *Cell Host Microbe.* 2017;22(6):801-8 e3.

670 32. Federici S, Kredo-Russo S, Valdes-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, et al.
671 Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for
672 treatment of intestinal inflammation. *Cell.* 2022;185(16):2879-98 e24.

673 33. Lourenco M, Chaffringeon L, Lamy-Besnier Q, Titecat M, Pedron T, Sismeiro O, et al. The gut
674 environment regulates bacterial gene expression which modulates susceptibility to bacteriophage
675 infection. *Cell Host Microbe.* 2022;30(4):556-69 e5.

676 34. Ng KM, Ferreyra JA, Higginbottom SK, Lynch JB, Kashyap PC, Gopinath S, et al. Microbiota-
677 liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. *Nature.*
678 2013;502(7469):96-9.

679 35. De Smet J, Zimmermann M, Kogadeeva M, Ceyssens PJ, Vermaelen W, Blasdel B, et al. High
680 coverage metabolomics analysis reveals phage-specific alterations to *Pseudomonas aeruginosa*
681 physiology during infection. *ISME J.* 2016;10(8):1823-35.

682 36. Liou MJ, Miller BM, Litvak Y, Nguyen H, Natwick DE, Savage HP, et al. Host cells subdivide
683 nutrient niches into discrete biogeographical microhabitats for gut microbes. *Cell Host Microbe.*
684 2022;30(6):836-47 e6.

685 37. Jakobsen RR, Trinh JT, Bomholtz L, Brok-Lauridsen SK, Sulakvelidze A, Nielsen DS. A
686 Bacteriophage Cocktail Significantly Reduces *Listeria monocytogenes* without deleterious Impact on
687 the Commensal Gut Microbiota under Simulated Gastrointestinal Conditions. *Viruses.* 2022;14(2).

688 38. Attai H, Wilde J, Liu R, Chopyk J, Garcia AG, Allen-Vercoe E, et al. Bacteriophage-Mediated
689 Perturbation of Defined Bacterial Communities in an In Vitro Model of the Human Gut. *Microbiol*
690 *Spectr.* 2022;e0113522.

691 39. Dini C, Bolla PA, de Urraza PJ. Treatment of in vitro enterohemorrhagic *Escherichia coli*
692 infection using phage and probiotics. *J Appl Microbiol.* 2016;121(1):78-88.

693 40. Shimamori Y, Mitsunaka S, Yamashita H, Suzuki T, Kitao T, Kubori T, et al. Staphylococcal
694 Phage in Combination with *Staphylococcus Epidermidis* as a Potential Treatment for *Staphylococcus*
695 *Aureus*-Associated Atopic Dermatitis and Suppressor of Phage-Resistant Mutants. *Viruses.*
696 2020;13(1).

697 41. Nappier SP, Hong T, Ichida A, Goldstone A, Eftim SE. Occurrence of coliphage in raw
698 wastewater and in ambient water: A meta-analysis. *Water Res.* 2019;153:263-73.

699 42. Hoiseth SK, Stocker BA. Aromatic-dependent *Salmonella typhimurium* are non-virulent and
700 effective as live vaccines. *Nature.* 1981;291(5812):238-9.

701 43. Maier L, Vyas R, Cordova CD, Lindsay H, Schmidt TS, Brugiroux S, et al. Microbiota-derived
702 hydrogen fuels *Salmonella typhimurium* invasion of the gut ecosystem. *Cell Host Microbe.*
703 2013;14(6):641-51.

704 44. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new
705 genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol.*
706 2012;19(5):455-77.

707 45. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics.* 2014;30(14):2068-
708 9.

709 46. Meier-Kolthoff JP, Goker M. VICTOR: genome-based phylogeny and classification of
710 prokaryotic viruses. *Bioinformatics.* 2017;33(21):3396-404.

711 47. Korf IHE, Meier-Kolthoff JP, Adriaenssens EM, Kropinski AM, Nimtz M, Rohde M, et al. Still
712 Something to Discover: Novel Insights into *Escherichia coli* Phage Diversity and Taxonomy. *Viruses.*
713 2019;11(5).

714 48. Herp S, Brugiroux S, Garzetti D, Ring D, Jochum LM, Beutler M, et al. *Mucispirillum schaedleri*
715 Antagonizes *Salmonella* Virulence to Protect Mice against Colitis. *Cell Host Microbe.* 2019;25(5):681-
716 94 e8.

717 49. Han J, Lin K, Sequeira C, Borchers CH. An isotope-labeled chemical derivatization method for
718 the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass
719 spectrometry. *Anal Chim Acta.* 2015;854:86-94.

720 50. Stecher B, Robbiani R, Walker AW, Westendorf AM, Barthel M, Kremer M, et al. *Salmonella*
721 *enterica* serovar *typhimurium* exploits inflammation to compete with the intestinal microbiota. *PLoS*
722 *Biol.* 2007;5(10):2177-89.

723 51. Garzetti D, Brugiroux S, Bunk B, Pukall R, McCoy KD, Macpherson AJ, et al. High-Quality
724 Whole-Genome Sequences of the Oligo-Mouse-Microbiota Bacterial Community. *Genome Announc.*
725 2017;5(42).

726 52. Seeman T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics.*
727 2014:<https://doi.org/10.1093/bioinformatics/btu153>.

728 53. Pruesse E, Peplies J, Glockner FO. SINA: accurate high-throughput multiple sequence
729 alignment of ribosomal RNA genes. *Bioinformatics.* 2012;28(14):1823-9.

730 54. Revell L. phytools: an R package for phylogenetic comparative biology (and other things).
731 *Methods in Ecology and Evolution.* 2012:<https://doi.org/10.1111/j.2041-210X.11.00169.x>.

732 55. Letunic I, Bork P. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display
733 and annotation. *Bioinformatics.* 2007;23(1):127-8.

734

735

736

737

738

739 **Main figure legends**

740 **Fig. 1: Phages specifically target their hosts in vivo**

741 (A) Experimental setup batch culture. The OMM¹⁴ strains were grown in monoculture, mixed
742 at the same OD₆₀₀ ratio and diluted every day 1:100 in AF medium. 12 hours after the third
743 passage, phage cocktails 3Φ^{Mt1B1} or 3Φ^{KB1} were added to the wells of a 24 well microtiter plate.
744 Before each dilution, samples were taken for plating and qPCR. (B) *E. coli* Mt1B1 and (C) *E.*
745 *faecalis* KB1 loads determined by plating (Log₁₀ CFU/ml). (D) Phage loads were determined
746 via spot assays on host strains *E. coli* Mt1B1 or *E. faecalis* KB1, respectively. (E) Community
747 composition 12 h and 36 h after phage addition, absolute abundance of each strain was
748 determined using a strain-specific qPCR and plotted as 16S rRNA copy numbers per ml culture.
749 Statistical analysis was performed using the Mann-Whitney Test comparing the treatment
750 groups (N=10) against the control group (N=10) (* p<0.05, ** p<0.01, *** p<0.001). Each dot
751 represents one well, black lines indicate median, dotted lines indicate detection limit (DTL).
752 The experiment was conducted in two biological replicates with ten technical replicates in total.

753

754 **Fig. 2: *E. coli* Mt1B1 and *E. faecalis* KB1 can be specifically targeted by phage-cocktails**
755 ***in vivo* in OMM¹⁴ mice**

756 (A) Experimental setup, mice stably colonized with the OMM¹⁴ community were challenged
757 orally with phage cocktails 3Φ^{Mt1B1} or 3Φ^{KB1} or PBS as control (10⁷ PFU per phage) and feces
758 were collected every day. On day 7 post phage challenge (p.c.), the mice were sacrificed. (B)
759 Phage loads (PFU/g feces) were determined via spot assays. (C) *E. coli* Mt1B1 and (D)
760 *E. faecalis* KB1 loads were determined by qPCR in fecal samples at different time points p.c..
761 (E) Absolute quantification of all other members of the OMM¹⁴ consortium on day 2 p.c. by
762 strain-specific qPCR (16S rRNA copies/g feces). Statistical analysis was performed using the
763 Mann-Whitney Test comparing the treatment groups (N=6) against the control group (N=4) (*
764 p<0.05, ** p<0.01, *** p<0.001). Each dot represents one mouse, black lines indicate median,
765 dotted lines indicate limit of detection.

766

767 **Fig. 3: Treatment with phage cocktails targeting *E. coli* and *E. faecalis* leads to increased**
768 ***S. Tm* loads after infection of OMM¹⁴ mice**

769 (A) Experimental setup, mice stably colonized with the OMM¹⁴ community were infected with
770 *S. Tm*^{avir} (5x10⁷ CFU) and directly after challenged orally with phage cocktails 3Φ^{Mt1B1} or
771 3Φ^{KB1} (10⁷ PFU per phage) or PBS as control. Feces were taken at day one and two p.c. and
772 mice were sacrificed at day two p.c.. (B) *E. coli* Mt1B1 and (C) *E. faecalis* KB1 loads (CFU/g
773 feces) were determined in feces by plating. (D) Phage loads (PFU/g feces) were determined by
774 spot assays. (E, F) *S. Tm*^{avir} loads at day 1 and 2 after phage challenge (= day 1 and 2 post
775 infection (p.i.)). Statistical analysis was performed using the Mann-Whitney Test (* p<0.05, **
776 p<0.01, *** p<0.001, N=6-8). Each dot represents one mouse, black lines indicate median,
777 dotted lines indicate limit of detection.

778

779 **Fig. 4: Treatment with phage cocktail targeting *E. faecalis* facilitates *S. Tm* induced
780 colitis in OMM¹⁴ mice**

781 (A) Experimental setup, mice stably colonized with the OMM¹⁴ community were challenged
782 orally with phage cocktails 3Φ^{Mt1B1} or 3Φ^{KB1} or PBS as control (10⁷ PFU per phage) and
783 infected with *S. Tm*^{wt} (5x10⁷ CFU). Feces were taken at day 1-3 p.c. and mice were sacrificed
784 at day 4 p.c. (B) *E. coli* Mt1B1, (C) *E. faecalis* KB1 and (D) *S. Tm*^{wt} loads (CFU/g) were
785 determined in feces by plating. (E) Histopathological score of the cecum at day 4. (F)
786 Inflammation levels were determined by measuring the Lipocalin-2 (ng/mg feces) levels in the
787 feces, utilizing a specific ELISA. Statistical analysis was performed using the Mann-Whitney
788 Test (* p<0.05, ** p<0.01, *** p<0.001, N=6-8). Each dot represents one mouse, black lines
789 indicate median, dotted lines indicate limit of detection.

790

791 **Fig. 5: Phages impair colonization resistance at late time points independently of changing
792 abundance of protective bacteria**

793 (A) Experimental setup, mice stably colonized with the OMM¹⁴ community were challenged
794 orally with phage cocktails 3Φ^{Mt1B1} or 3Φ^{KB1} (10⁷ PFU per phage) or PBS as control and
795 infected with *S. Tm*^{avir} (5x10⁷ CFU) at day 7 p.c.. Feces were taken at day 1, 2, 7, 8 and 9 p.c.
796 and mice were sacrificed at day 9 p.c. (corresponding to day two p.i.). (B) *E. coli* Mt1B1 and
797 (C) *E. faecalis* KB1 loads (CFU/g) were determined in feces by plating. (D) Phage loads (PFU/g
798 feces) of 3Φ^{Mt1B1} phages and 3Φ^{KB1} phages were determined by spot assays in fecal samples at
799 different time points p.c.. (E) *S. Tm*^{avir} loads at day 8 and 9 p.c. (= day 1 and 2 p.i.). Statistical
800 analysis was performed using the Mann-Whitney Test (* p<0.05, ** p<0.01, *** p<0.001, N=4-
801 6). Each dot represents one mouse, black lines indicate median, dotted lines indicate limit of
802 detection.

803

804

805

806

807

808

809

810


811

812

813


814

815




816

817 **Fig 1**




818

819 **Fig 2**



820

821 **Fig 3**



822

823 **Fig 4**

